ORIA is pleased to announce the long awaited launch of ERA IBC! The new ERA IBC module is anticipated to launch in mid-October 2020 for new IBC disclosures. The ERA IBC module will streamline the biosafety disclosure submission, review, and approval process significantly as all information will reside in a single electronic system. More information will be coming soon. If you have questions about the upcoming launch of ERA IBC please don’t hesitate to contact us at IBC@asu.edu.
The Institutional Biosafety Committee (IBC) is responsible for the review and oversight of research or teaching conducted under the auspices of Arizona State University that utilizes recombinant or synthetic nucleic acid molecules, biohazards or infectious agents, select agents and toxins, or dual use research of concern (DURC).
The IBC has established and implemented policies and procedures to provide for the safe and ethical conduct of research and teaching activities involving all biohazards and to facilitate compliance with the National Institutes of Health’s “Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules,” and other university, sponsor, federal, state, and local laws and regulations.
The IBC is supported and administered through the Office of Research Integrity and Assurance (ORIA). Environmental Health & Safety’s (EH&S) Biosafety and Biosecurity unit supports the IBC through training, expertise, and laboratory inspections. In working together, we are committed to support ASU’s culture of safety.